Stock VLG VENTURE LIFE GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Venture Life Group plc

Equities

VLG

GB00BFPM8908

Pharmaceuticals

Delayed London S.E.
Other stock markets
 07:35:34 2024-06-18 EDT 		5-day change 1st Jan Change
41.5 GBX +1.22% Intraday chart for Venture Life Group plc +2.47% +23.88%
06-04 Venture Life confident in outlook for year; performs in line AN
04-19 Venture Life renews revolving credit facility with Santander and HSBC AN

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 28.04 117 37.75 46.17 42.38 51.93 - -
Enterprise Value (EV) 1 24.36 86.11 45.24 62.47 56.08 61.1 53.81 44.43
P/E ratio 33.2 x 36.8 x 16.8 x 93.6 x 49.3 x 22.3 x 12.4 x 9.58 x
Yield - - - - - - - -
Capitalization / Revenue 1.39 x 3.89 x 1.15 x 1.05 x 0.82 x 0.94 x 0.87 x 0.81 x
EV / Revenue 1.21 x 2.86 x 1.38 x 1.42 x 1.09 x 1.11 x 0.91 x 0.69 x
EV / EBITDA 9.22 x 15.5 x 7.06 x 7.03 x 4.85 x 5.22 x 4.12 x 3.08 x
EV / FCF - 59.1 x 197 x 13.3 x 7.58 x 9.95 x 6.88 x 4.53 x
FCF Yield - 1.69% 0.51% 7.53% 13.2% 10% 14.5% 22.1%
Price to Book - 1.62 x 0.52 x 0.61 x 0.56 x 0.66 x 0.62 x 0.58 x
Nbr of stocks (in thousands) 83,712 125,832 125,832 126,498 126,498 126,648 - -
Reference price 2 0.3350 0.9300 0.3000 0.3650 0.3350 0.4100 0.4100 0.4100
Announcement Date 4/9/20 3/25/21 5/17/22 4/4/23 4/9/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 20.21 30.08 32.76 43.98 51.41 55.02 59.42 64.47
EBITDA 1 2.643 5.545 6.404 8.89 11.56 11.69 13.08 14.4
EBIT 1 1.278 3.555 1.371 3.505 3.289 4.68 6.061 7.269
Operating Margin 6.32% 11.82% 4.18% 7.97% 6.4% 8.51% 10.2% 11.27%
Earnings before Tax (EBT) 1 1.362 3.276 0.946 0.706 1.123 3.08 5.534 7.167
Net income 1 0.904 2.368 2.402 0.52 0.921 2.495 4.483 5.805
Net margin 4.47% 7.87% 7.33% 1.18% 1.79% 4.53% 7.54% 9%
EPS 2 0.0101 0.0253 0.0179 0.003900 0.006800 0.0184 0.0330 0.0428
Free Cash Flow 1 - 1.458 0.23 4.706 7.4 6.138 7.818 9.814
FCF margin - 4.85% 0.7% 10.7% 14.39% 11.16% 13.16% 15.22%
FCF Conversion (EBITDA) - 26.29% 3.59% 52.94% 64.03% 52.49% 59.79% 68.14%
FCF Conversion (Net income) - 61.57% 9.58% 905% 803.47% 246.01% 174.39% 169.06%
Dividend per Share - - - - - - - -
Announcement Date 4/9/20 3/25/21 5/17/22 4/4/23 4/9/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2022 S1 2023 S1
Net sales 16.9 18.86 -
EBITDA 3.163 - -
EBIT 2.28 - -
Operating Margin 13.49% - -
Earnings before Tax (EBT) - - -
Net income 1 - - -1.508
Net margin - - -
EPS 2 - - -0.0119
Dividend per Share - - -
Announcement Date 9/24/20 9/22/22 9/25/23
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 7.49 16.3 13.7 9.17 1.89 -
Net Cash position 1 3.69 30.9 - - - - - 7.49
Leverage (Debt/EBITDA) - - 1.17 x 1.834 x 1.185 x 0.7842 x 0.1445 x -
Free Cash Flow 1 - 1.46 0.23 4.71 7.4 6.14 7.82 9.81
ROE (net income / shareholders' equity) - - - - 9.3% 9.4% 11.2% 11.9%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 0.5700 0.5800 0.6000 0.6000 0.6300 0.6600 0.7100
Cash Flow per Share 0.0300 - - - - - - -
Capex 1 0.39 1.25 0.37 0.86 0.82 2.8 2.26 1.48
Capex / Sales 1.92% 4.15% 1.13% 1.96% 1.6% 5.09% 3.8% 2.3%
Announcement Date 4/9/20 3/25/21 5/17/22 4/4/23 4/9/24 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Venture Life Group plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VENTURE LIFE GROUP PLC Stock Venture Life Group plc
+23.88% 65.89M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.82% 797B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.55% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.88% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.95% 323B
ABBVIE INC. Stock AbbVie Inc.
+9.49% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.04% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+0.90% 223B
AMGEN INC. Stock Amgen Inc.
+5.30% 163B
PFIZER, INC. Stock Pfizer, Inc.
-6.29% 153B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VLG Stock
  4. Financials Venture Life Group plc